Pfizer Inc. (TSX:PFE)

Revenue

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Jun 28, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Primary Care Revenue	26.63B	26.82B	30.14B
Specialty Care Revenue (Pre-FY2026 Reporting)	-	17.55B	16.65B
Oncology Revenue (Pre-FY2026 Reporting)	-	16.83B	15.61B
Global Pharmaceuticals Business (Biopharma) Revenue	62.28B	61.20B	62.40B
Business Innovation (Pfizer CentreOne) Revenue	1.42B	1.34B	1.15B
Revenue (Other)	5.00M	42.00M	81.00M
Revenue (Total)	63.70B	62.58B	63.63B

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Jun 28, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
United States Revenue	37.40B	37.08B	38.69B
Developed Markets Revenue	16.79B	16.19B	16.06B
Emerging Markets Revenue	9.51B	9.31B	8.88B
Revenue (Other)	1.00M	-	-
Revenue (Total)	63.70B	62.58B	63.63B

Revenue by Geography 2

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Jun 28, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
United States Revenue	37.40B	37.08B	38.69B
Revenue (Total)	63.70B	62.58B	63.63B

Revenue by Geography 3

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Jun 28, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
United States Revenue	37.40B	37.08B	38.69B
International Revenue	26.30B	25.50B	24.94B
Revenue (Total)	63.70B	62.58B	63.63B

EBT

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Jun 28, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Global Pharmaceuticals Business (Biopharma) Earnings	29.03B	29.34B	27.97B
Other Business Activities Earnings	-8.36B	-8.20B	-7.21B

Key Performance Indicators

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Jun 28, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Comirnaty - Direct Sales and Alliance Revenue	3.92B	4.37B	5.35B
Eliquis - Direct Sales and Alliance Revenue	8.63B	7.96B	7.37B
Paxlovid Revenue	1.65B	2.36B	5.72B
Prevnar Family Revenue	6.48B	6.49B	6.41B
Nurtec ODT/Vydura Revenue	1.59B	1.42B	1.26B
Abrysvo Revenue	1.15B	1.03B	755.00M
Vyndaqel Family Revenue	6.64B	6.38B	5.45B
Xeljanz Revenue	1.07B	1.09B	1.17B
Ibrance Revenue	4.16B	4.12B	4.37B

Data Source: Fiscal.ai Last updated: Jun 28, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 25, 2026

Data Sources Report a data error